Collaborations & Alliances

Kite Pharma and Alpine Immune Sciences Form Pact

Kite to exclusively license transmembrane immunomodulatory protein technology for applications to CAR and TCR programs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Kite Pharma Inc. has entered into a worldwide research and license agreement with Alpine Immune Sciences Inc. (AIS), a privately-held biotechnology company, to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. AIS will grant Kite an exclusive license to two programs from its transmembrane immunomodulatory protein (TIP) technology, which Kite plans to further engineer into chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters